Compare LOMA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOMA | ANL |
|---|---|---|
| Founded | 1926 | 2004 |
| Country | Argentina | Singapore |
| Employees | N/A | N/A |
| Industry | Building Materials | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 998.8M |
| IPO Year | 2017 | 2022 |
| Metric | LOMA | ANL |
|---|---|---|
| Price | $9.16 | $15.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $14.30 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 308.4K | 139.1K |
| Earning Date | 11-05-2026 | 08-14-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.53 | $243.83 |
| Revenue Next Year | $10.89 | N/A |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.28 | $0.88 |
| 52 Week High | $13.20 | $17.25 |
| Indicator | LOMA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 31.01 | 56.23 |
| Support Level | N/A | $12.45 |
| Resistance Level | $12.05 | $17.25 |
| Average True Range (ATR) | 0.29 | 1.01 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 1.64 | 43.34 |
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The Group is engaged in the production and distribution of cement, masonry cement, concrete, limestone, and aggregates, operates a railway concession to provide transportation services, and is also engaged in the industrial waste recycling business. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.